Compare · BDX vs KRMD
BDX vs KRMD
Side-by-side comparison of Becton Dickinson and Company (BDX) and KORU Medical Systems Inc. (KRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.38B, about 224.1x KRMD ($184.7M).
- Over the past year, BDX is down 29.8% and KRMD is up 44.4% - KRMD leads by 74.1 points.
- BDX has been more active in the news (14 items in the past 4 weeks vs 3 for KRMD).
- BDX has more recent analyst coverage (25 ratings vs 6 for KRMD).
- Company
- Becton Dickinson and Company
- KORU Medical Systems Inc.
- Price
- $145.31-2.82%
- $3.97-2.22%
- Market cap
- $41.38B
- $184.7M
- 1M return
- -6.06%
- -6.37%
- 1Y return
- -29.78%
- +44.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 3
- Recent ratings
- 25
- 6
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
KORU Medical Systems Inc.
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Latest BDX
- Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,244 worth of shares (74 units at $151.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,159 units (SEC Form 4)
- BD to Present at Bank of America Securities Health Care Conference
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD
Latest KRMD
- KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form DEF 14A filed by KORU Medical Systems Inc.
- Amendment: SEC Form 4 filed by Manko Joseph M. Jr.
- KORU Medical Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 4 filed by Wholihan Edward
- SEC Form 4 filed by Cascella Robert
- SEC Form 4 filed by French Donna
- SEC Form 4 filed by Matin Shahriar
- SEC Form 4 filed by Fletcher R John
- SEC Form 4 filed by Manko Joseph M. Jr.